<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03283501</url>
  </required_header>
  <id_info>
    <org_study_id>001-2017</org_study_id>
    <nct_id>NCT03283501</nct_id>
  </id_info>
  <brief_title>Revascularization After Transcatheter Aortic Valve Implantation (REVIVAL)</brief_title>
  <acronym>REVIVAL</acronym>
  <official_title>A Multicenter Observational Registry on Coronary Revascularization After Implantation of Transcatheter Aortic Valve Bioprosthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Luigi Gonzaga Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>San Luigi Gonzaga Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate incidence, clinical indications, and feasibility of PCI performed after TAVI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The increasing operator experience combined with an improved performance of devices have led
      to extend current transcatheter aortic valve implantation (TAVI) indications to patients at
      low or intermediate risk. The safety of TAVI in this population was initially tested in small
      observational studies and recently reported in the randomized PARTNER 2 and Surgical
      Replacement and Transcatheter Aortic Valve Implantation Trial (SURTAVI) trials, which
      demonstrated non- inferiority of TAVI in low or intermediate risk patients as compared to
      surgery with respect to the primary endpoint of death or disabling stroke. In view of the
      changes in the TAVI population, including younger patients with longer survival, the number
      of patients that may require coronary revascularization after TAVI is expected to increase
      over the time. Of note, challenges in performing percutaneous coronary interventions (PCI) in
      patients previously treated with TAVI have been reported in small series.

      Against this background, the purpose of this retrospective multicenter study is to evaluate
      incidence, clinical indications, and feasibility of PCI performed after TAVI.

      Objectives

        1. Evaluate the incidence of PCI after TAVI

        2. Evaluate the clinical indications for PCI after TAVI

        3. Evaluate the technical feasibility of PCI in patients with prior TAVI

        4. Evaluate in-hospital and long-term clinical outcomes in patients undergoing PCI after
           TAVI
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the incidence of PCI after TAVI</measure>
    <time_frame>up to 5 year after TAVI implantation</time_frame>
    <description>Evaluate the incidence of PCI after TAVI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the clinical indications for PCI after TAVI</measure>
    <time_frame>intraoperative</time_frame>
    <description>Clinical indication for PCI: stable angina; documented silent ischemia; acute coronary syndrome/non-ST elevation myocardial infarction; acute coronary syndrome/ST elevation myocardial infarction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the technical feasibility of PCI in patients with prior TAVI</measure>
    <time_frame>intraoperative</time_frame>
    <description>Successful target coronary vessel revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate in-hospital and long-term clinical outcomes in patients undergoing PCI after TAVI</measure>
    <time_frame>up to 5 year after TAVI implantation</time_frame>
    <description>outcome defined as MACE (Major Adverse Coronary Event) a composite of Death, Myocardial Infarction, Target Lesion Failure</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Transcatheter Valve Implantation</condition>
  <condition>TAVI</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI after TAVI</intervention_name>
    <description>Any patient undergoing PCI after TAVI, irrespective of clinical indications and irrespective of whether planned or not at the time of TAVI</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient undergoing PCI after TAVI, irrespective of clinical indications and
        irrespective of whether planned or not at the time of TAVI
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient undergoing PCI after TAVI, irrespective of clinical indications and
             irrespective of whether planned or not at the time of TAVI

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Humanitas Research Hospital, Humanitas University</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulio Stefanini, MD, PhD</last_name>
      <phone>+390282241</phone>
      <email>giulio.stefanini@hunimed.eu</email>
    </contact>
    <investigator>
      <last_name>Giulio Stefanini, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interventional Unit, San Luigi Gonzaga University Hospital, Orbassano, and Rivoli Hospital, Turin, Italy</name>
      <address>
        <city>Turin</city>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Cerrato, MD</last_name>
      <phone>+390119026602</phone>
      <email>enrico.cerrato@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Enrico Cerrato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Nombela-Franco, MD,PhD</last_name>
      <phone>+34 91 330 30 00</phone>
      <email>luisnombela@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Luis Nombela-Franco, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://cardiogroup.org</url>
    <description>Organization research website</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2017</study_first_submitted>
  <study_first_submitted_qc>September 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Luigi Gonzaga Hospital</investigator_affiliation>
    <investigator_full_name>Enrico Cerrato</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>PCI</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

